Equites Radar

TWST · Twist Bioscience Corporation

Diagnostics & ResearchUnited StatesAnalyst view: Buy

$90.27

+2.32% last session

End-of-day data · updated 2026-07-28

Mildly bullish3 bullish · 1 bearish technical signals
Consensus: Buy (1.55 from 10 analysts)
To mean target: +2.5%

Market cap

$5B

Enterprise value

$6B

Trailing P/E

Forward P/E

-101.8

Dividend yield

Beta

2.12

Avg volume

2M

Employees

1K

2D change

-4.13%

5D change

-6.38%

10D change

-7.79%

30D change

-13.32%

60D change

29.42%

MTD change

-15.36%

YTD change

172.82%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.55
Covering analysts10
Mean price target$92.50
Low price target$36.00
Upside to mean target+2.5%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)49.6
50-day MA$80.36
200-day MA$51.42
Price vs 50-day MA+10.2%
Price vs 200-day MA+72.2%
MACD histogram-1.55
Volume vs 3-month avg0.8×
52w low $24.1652w high $102.88

Analyst sentiment over time — TWST

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-14

Latest call per bank · past 12 months

Barclays

Overweight

$95.00

+5.2% vs price
▲ raised from $65.00Maintains · 2026-06-24

Recent rating actions

DateFirmActionRatingPrice target
2026-07-14Canaccord GenuityMaintainsBuy$90.00 $120
2026-07-06Evercore ISI GroupDowngradeOutperformIn-Line$66.00 $102
2026-06-29GuggenheimMaintainsBuy$60.00 $107
2026-06-24BarclaysMaintainsOverweight$65.00 $95.00
2026-06-15TD CowenMaintainsBuy$68.00 $89.00
2026-06-15Canaccord GenuityInitiatesBuy$0.00 $90.00
2026-06-11Piper SandlerInitiatesOverweight$0.00 $85.00
2026-05-05Leerink PartnersUpgradeMarket PerformOutperform$0.00 $70.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 10.2% above the 50-day MA ($80.36).
  • Price vs 200-day MA: Trading 72.2% above the 200-day MA ($51.42).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-1.55) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($24.16) and high ($102.88).

TWST Price Chart

Loading chart for TWST

Fundamentals

Revenue (TTM)$0M
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$7.32
Net debt / EBITDA0.6
WACC18.0%
Revenue growth19.00%
Earnings growth

About Twist Bioscience Corporation

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More in Diagnostics & Research

Screen TWST against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.